Avastin News and Research

RSS

Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).

Study shows that antiangiogenic agent delays progression of advanced breast cancer

The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.

28 Dec 2007

Bevacizumab found to improve survival for patients with advanced breast cancer

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy.

28 Dec 2007

Cancer stem cells may be at the root of brain tumors

Stem cells -- popularly known as a source of biological rejuvenation -- may play harmful roles in the body, specifically in the growth and spread of cancer. Amongst the wildly dividing cells of a tumor, scientists have located cancer stem cells.

27 Dec 2007

Avastin shows promise for brain cancer

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

17 Dec 2007

Drug study for brain cancer shows promising results

14 Dec 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Block buster cancer drug Avastin gives hope to brain tumor victims

According to a new study the blockbuster cancer drug Avastin has shown promising results in treating brain cancer victims.

19 Nov 2007

New approaches to wet age-related macular degeneration treatment

Two particularly notable research presentations at the American Academy of Ophthalmology's Annual Meeting described new approaches to the treatment of "wet" Age-Related Macular Degeneration (AMD), the most common cause of severe vision loss in the western world in people over age 50.

13 Nov 2007

Light activated magic bullets zap out cancers

Scientists in Britain believe they may be able to use ultra-violet light to render cancer-fighting drugs far more effective.

30 Oct 2007

Positive results for novel anti-cancer drug ECO-4601

Researchers report positive results from a Phase I/II clinical trial of a novel anti-cancer drug which offers two modes of action.

24 Oct 2007

Avastin and chemo combo may offer hope for glioblastoma multiforme patients

Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme (GBM) -- may survive longer with a drug that chokes off a tumor's blood supply.

19 Oct 2007

Cancer trial combines multiple drugs to attack blood vessel formation in patients with kidney cancer

In the first clinical trial of its kind, researchers at the University of Pennsylvania School of Medicine and the Abramson Cancer Center will lead a nationwide test of anti-cancer drug combinations that target blood vessel growth in patients with advanced kidney cancer.

4 Oct 2007

Some cancer cells mimic stem cells to evade chemotherapy

Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

25 Sep 2007

Some cancer cells mimic stem cells to evade chemotherapy

Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented in Atlanta, Georgia at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

20 Sep 2007